01. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet (London, England) 387, 1377–1396 (2016).
02. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet (London, England) 390, 2627–2642 (2017).
03. Kopelman, P. G. Obesity as a medical problem. Nature 404, 635–43 (2000).
04. Haslam, D. W. & James, W. P. T. Obesity. Lancet (London, England) 366, 1197–209 (2005).
05. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–6 (2006).
06. Van Gaal, L. F., Mertens, I. L. & De Block, C. E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875–80 (2006).
07. Magkos, F. et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 23, 591–601 (2016).
08. Hamman, R. F. et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29, 2102–7 (2006).
09. Sun, Q. et al. Comparison of dual-energy x-ray absorptiometric and anthropometric measures of adiposity in relation to adiposity-related biologic factors. Am. J. Epidemiol. 172, 1442–54 (2010).
10. Prentice, A. M. & Jebb, S. A. Beyond body mass index. Obes. Rev. 2, 141–7 (2001).
11. Okorodudu, D. O. et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: A systematic review and meta-analysis. Int. J. Obes. 34, 791–799 (2010).
12. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England) 363, 157–63 (2004).
13. Ruderman, N., Chisholm, D., Pi-Sunyer, X. & Schneider, S. The metabolically obese, normal-weight individual revisited. Diabetes 47, 699–713 (1998).
14. Ding, C., Chan, Z. & Magkos, F. Lean, but not healthy: the 'metabolically obese, normal-weight' phenotype. Curr. Opin. Clin. Nutr. Metab. Care 19, 408–417 (2016).
15. Smith, G. I., Mittendorfer, B. & Klein, S. Metabolically healthy obesity: facts and fantasies. J. Clin. Invest. 129, 3978–3989 (2019).
16. Appleton, S. L. et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 36, 2388–94 (2013).
17. Schröder, H. et al. Determinants of the transition from a cardiometabolic normal to abnormal overweight/obese phenotype in a Spanish population. Eur. J. Nutr. 53, 1345–53 (2014).
18. Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat. Med. 25, 1851–1857 (2019).
19. Bar, N. et al. A reference map of potential determinants for the human serum metabolome. Nature 588, 135–140 (2020).
20. Wilmanski, T. et al. Blood metabolome predicts gut microbiome α-diversity in humans. Nat. Biotechnol. 37, 1217–1228 (2019).
21. Cirulli, E. T. et al. Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. Cell Metab. 29, 488-500.e2 (2019).
22. Talmor-Barkan, Y. et al. Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease. Nat. Med. 28, 295–302 (2022).
23. Nimptsch, K., Konigorski, S. & Pischon, T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 92, 61–70 (2019).
24. Price, N. D. et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat. Biotechnol. 35, 747–756 (2017).
25. Zubair, N. et al. Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program. Sci. Rep. 9, 6805 (2019).
26. Earls, J. C. et al. Multi-Omic Biological Age Estimation and Its Correlation With Wellness and Disease Phenotypes: A Longitudinal Study of 3,558 Individuals. J. Gerontol. A. Biol. Sci. Med. Sci. 74, S52–S60 (2019).
27. Wainberg, M. et al. Multiomic blood correlates of genetic risk identify presymptomatic disease alterations. Proc. Natl. Acad. Sci. U. S. A. 117, 21813–21820 (2020).
28. Wilmanski, T. et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat. Metab. 3, 274–286 (2021).
29. Zimmer, A. et al. The geometry of clinical labs and wellness states from deeply phenotyped humans. Nat. Commun. 12, 3578 (2021).
30. Tibshirani, R. Regression Shrinkage and Selection Via the Lasso. J. R. Stat. Soc. Ser. B 58, 267–288 (1996).
31. Moayyeri, A., Hammond, C. J., Valdes, A. M. & Spector, T. D. Cohort Profile: TwinsUK and healthy ageing twin study. Int. J. Epidemiol. 42, 76–85 (2013).
32. Long, T. et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat. Genet. 49, 568–578 (2017).
33. Xu, X. et al. Habitual sleep duration and sleep duration variation are independently associated with body mass index. Int. J. Obes. (Lond). 42, 794–800 (2018).
34. Stefan, N., Schick, F. & Häring, H.-U. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 26, 292–300 (2017).
35. Blüher, M. Metabolically Healthy Obesity. Endocr. Rev. 41, 405–420 (2020).
36. Shah, N. R. & Braverman, E. R. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS One 7, e33308 (2012).
37. Tomiyama, A. J., Hunger, J. M., Nguyen-Cuu, J. & Wells, C. Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005-2012. Int. J. Obes. (Lond). 40, 883–6 (2016).
38. Bennett, C. M., Guo, M. & Dharmage, S. C. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet. Med. 24, 333–43 (2007).
39. Pereira-Santos, M., Costa, P. R. F., Assis, A. M. O., Santos, C. A. S. T. & Santos, D. B. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes. Rev. 16, 341–9 (2015).
40. Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).
41. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).
42. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).
43. Walters, W. A., Xu, Z. & Knight, R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 588, 4223–4233 (2014).
44. Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).
45. Visconti, A. et al. Interplay between the human gut microbiome and host metabolism. Nat. Commun. 10, 4505 (2019).
46. Diener, C. et al. Baseline Gut Metagenomic Functional Gene Signature Associated with Variable Weight Loss Responses following a Healthy Lifestyle Intervention in Humans. mSystems 6, e0096421 (2021).
47. Karetnikova, E. S. et al. Is Homoarginine a Protective Cardiovascular Risk Factor? Arterioscler. Thromb. Vasc. Biol. 39, 869–875 (2019).
48. Dieuleveux, V., Lemarinier, S. & Guéguen, M. Antimicrobial spectrum and target site of D-3-phenyllactic acid. Int. J. Food Microbiol. 40, 177–83 (1998).
49. Beloborodova, N. et al. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J. Biomed. Sci. 19, 89 (2012).
50. Després, J.-P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881–7 (2006).
51. Ashwell, M., Gunn, P. & Gibson, S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes. Rev. 13, 275–86 (2012).
52. Swainson, M. G., Batterham, A. M., Tsakirides, C., Rutherford, Z. H. & Hind, K. Prediction of whole-body fat percentage and visceral adipose tissue mass from five anthropometric variables. PLoS One 12, e0177175 (2017).
53. Li, Y. et al. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides 28, 1129–43 (2007).
54. Egaña-Gorroño, L. et al. Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. Front. Cardiovasc. Med. 7, 37 (2020).
55. Norata, G. D. et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr. Metab. Cardiovasc. Dis. 19, 129–34 (2009).
56. Rauschert, S., Uhl, O., Koletzko, B. & Hellmuth, C. Metabolomic biomarkers for obesity in humans: A short review. Ann. Nutr. Metab. 64, 314–324 (2014).
57. Rangel-Huerta, O. D., Pastor-Villaescusa, B. & Gil, A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics 15, 93 (2019).
58. Barber, M. N. et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 7, e41456 (2012).
59. Piening, B. D. et al. Integrative Personal Omics Profiles during Periods of Weight Gain and Loss. Cell Syst. 6, 157-170.e8 (2018).
60. Koenig, R. J. et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N. Engl. J. Med. 295, 417–20 (1976).
61. Wing, R. R. & Phelan, S. Long-term weight loss maintenance. Am. J. Clin. Nutr. 82, 222S-225S (2005).
62. Li, G. et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet (London, England) 371, 1783–9 (2008).
63. Diabetes Prevention Program Research Group et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England) 374, 1677–86 (2009).
64. Yilmaz, P. et al. The SILVA and 'All-species Living Tree Project (LTP)' taxonomic frameworks. Nucleic Acids Res. 42, D643-8 (2014).
65. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884–i890 (2018).
66. Lu, J. et al. Metagenome analysis using the Kraken software suite. Nat. Protoc. 1–25 (2022). doi:10.1038/s41596-022-00738-y
67. Stekhoven, D. J. & Bühlmann, P. Missforest-Non-parametric missing value imputation for mixed-type data. Bioinformatics 28, 112–118 (2012).
68. Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
69. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837–45 (1988).
70. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. Circlize implements and enhances circular visualization in R. Bioinformatics 30, 2811–2812 (2014).